These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

182 related articles for article (PubMed ID: 38666024)

  • 21. Elexacaftor/Tezacaftor/Ivacaftor Treatment and Depression-related Events.
    Ramsey B; Correll CU; DeMaso DR; McKone E; Tullis E; Taylor-Cousar JL; Chu C; Volkova N; Ahluwalia N; Waltz D; Tian S; Mall MA
    Am J Respir Crit Care Med; 2024 Feb; 209(3):299-306. PubMed ID: 37890129
    [No Abstract]   [Full Text] [Related]  

  • 22. The cystic-fibrosis-associated ΔF508 mutation confers post-transcriptional destabilization on the C. elegans ABC transporter PGP-3.
    He L; Skirkanich J; Moronetti L; Lewis R; Lamitina T
    Dis Model Mech; 2012 Nov; 5(6):930-9. PubMed ID: 22569626
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Theratyping of the Rare CFTR Variants E193K and R334W in Rectal Organoid-Derived Epithelial Monolayers.
    Ciciriello F; Bijvelds MJC; Alghisi F; Meijsen KF; Cristiani L; Sorio C; Melotti P; Fiocchi AG; Lucidi V; De Jonge HR
    J Pers Med; 2022 Apr; 12(4):. PubMed ID: 35455747
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Annexin A5 increases the cell surface expression and the chloride channel function of the DeltaF508-cystic fibrosis transmembrane regulator.
    Le Drévo MA; Benz N; Kerbiriou M; Giroux-Metges MA; Pennec JP; Trouvé P; Férec C
    Biochim Biophys Acta; 2008 Oct; 1782(10):605-14. PubMed ID: 18773956
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Real world outcomes of CFTR modulator therapy in Australian adults and children.
    Kuek S; McCullagh A; Paul E; Armstrong D
    Pulm Pharmacol Ther; 2023 Oct; 82():102247. PubMed ID: 37574040
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Simultaneous Quantification of Ivacaftor, Tezacaftor, and Elexacaftor in Cystic Fibrosis Patients' Plasma by a Novel LC-MS/MS Method.
    Pigliasco F; Cafaro A; Stella M; Baiardi G; Barco S; Pedemonte N; D'Orsi C; Cresta F; Casciaro R; Castellani C; Calevo MG; Mattioli F; Cangemi G
    Biomedicines; 2023 Feb; 11(2):. PubMed ID: 36831163
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Small-molecule correctors of defective DeltaF508-CFTR cellular processing identified by high-throughput screening.
    Pedemonte N; Lukacs GL; Du K; Caci E; Zegarra-Moran O; Galietta LJ; Verkman AS
    J Clin Invest; 2005 Sep; 115(9):2564-71. PubMed ID: 16127463
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Targeting autophagy as a novel strategy for facilitating the therapeutic action of potentiators on ΔF508 cystic fibrosis transmembrane conductance regulator.
    Luciani A; Villella VR; Esposito S; Gavina M; Russo I; Silano M; Guido S; Pettoello-Mantovani M; Carnuccio R; Scholte B; De Matteis A; Maiuri MC; Raia V; Luini A; Kroemer G; Maiuri L
    Autophagy; 2012 Nov; 8(11):1657-72. PubMed ID: 22874563
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Conformational and temperature-sensitive stability defects of the delta F508 cystic fibrosis transmembrane conductance regulator in post-endoplasmic reticulum compartments.
    Sharma M; Benharouga M; Hu W; Lukacs GL
    J Biol Chem; 2001 Mar; 276(12):8942-50. PubMed ID: 11124952
    [TBL] [Abstract][Full Text] [Related]  

  • 30. ERp29 regulates DeltaF508 and wild-type cystic fibrosis transmembrane conductance regulator (CFTR) trafficking to the plasma membrane in cystic fibrosis (CF) and non-CF epithelial cells.
    Suaud L; Miller K; Alvey L; Yan W; Robay A; Kebler C; Kreindler JL; Guttentag S; Hubbard MJ; Rubenstein RC
    J Biol Chem; 2011 Jun; 286(24):21239-53. PubMed ID: 21525008
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Towards a rational combination therapy of cystic fibrosis: How cystamine restores the stability of mutant CFTR.
    Villella VR; Esposito S; Maiuri MC; Raia V; Kroemer G; Maiuri L
    Autophagy; 2013 Sep; 9(9):1431-4. PubMed ID: 23800975
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Pharmacological treatment of the ion transport defect in cystic fibrosis.
    Roomans GM
    Expert Opin Investig Drugs; 2001 Jan; 10(1):1-19. PubMed ID: 11116277
    [TBL] [Abstract][Full Text] [Related]  

  • 33. AAV exploits subcellular stress associated with inflammation, endoplasmic reticulum expansion, and misfolded proteins in models of cystic fibrosis.
    Johnson JS; Gentzsch M; Zhang L; Ribeiro CM; Kantor B; Kafri T; Pickles RJ; Samulski RJ
    PLoS Pathog; 2011 May; 7(5):e1002053. PubMed ID: 21625534
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Novel amino-carbonitrile-pyrazole identified in a small molecule screen activates wild-type and ΔF508 cystic fibrosis transmembrane conductance regulator in the absence of a cAMP agonist.
    Namkung W; Park J; Seo Y; Verkman AS
    Mol Pharmacol; 2013 Sep; 84(3):384-92. PubMed ID: 23788656
    [TBL] [Abstract][Full Text] [Related]  

  • 35. CFTR Modulators: Current Status and Evolving Knowledge.
    Regard L; Martin C; Da Silva J; Burgel PR
    Semin Respir Crit Care Med; 2023 Apr; 44(2):186-195. PubMed ID: 36535667
    [TBL] [Abstract][Full Text] [Related]  

  • 36. A domain mimic increases DeltaF508 CFTR trafficking and restores cAMP-stimulated anion secretion in cystic fibrosis epithelia.
    Clarke LL; Gawenis LR; Hwang TC; Walker NM; Gruis DB; Price EM
    Am J Physiol Cell Physiol; 2004 Jul; 287(1):C192-9. PubMed ID: 15028554
    [TBL] [Abstract][Full Text] [Related]  

  • 37. The use of elexacaftor/tezacaftor/ivacaftor in patients with cystic fibrosis postliver transplant: A case series.
    Ragan H; Autry E; Bomersback T; Hewlett J; Kormelink L; Safirstein J; Shanley L; Lubsch L
    Pediatr Pulmonol; 2022 Feb; 57(2):411-417. PubMed ID: 34850610
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Rescue of folding defects in ABC transporters using pharmacological chaperones.
    Loo TW; Bartlett MC; Clarke DM
    J Bioenerg Biomembr; 2005 Dec; 37(6):501-7. PubMed ID: 16691490
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Personalized medicine with drugs targeting the underlying protein defect in cystic fibrosis: is monitoring of treatment response necessary?
    Niedermayr K; Gasser V; Rueckes-Nilges C; Appelt D; Eder J; Fuchs T; Naehrlich L; Ellemunter H
    Ther Adv Chronic Dis; 2022; 13():20406223221108627. PubMed ID: 35959505
    [TBL] [Abstract][Full Text] [Related]  

  • 40. ΔF508-CFTR Modulator Screen Based on Cell Surface Targeting of a Chimeric Nucleotide Binding Domain 1 Reporter.
    Phuan PW; Veit G; Tan JA; Roldan A; Finkbeiner WE; Haggie PM; Lukacs GL; Verkman AS
    SLAS Discov; 2018 Sep; 23(8):823-831. PubMed ID: 29533733
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.